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Abstract
Background: The aim of this study was to determine influence of prognostic factors in addition
to UICC staging systems, on cancer-specific and overall survival rates for patients with colorectal
cancer (CRC) undergoing surgical treatment.
Methods: Between January 1996 and December 2006, a total of 1367 CRC patients who
underwent surgical treatment in Kaohsiung Medical University Hospital were analyzed. We
retrospectively investigated clinicopathologic features of these patients. All patients were followed
up intensively, and their outcomes were investigated completely.
Results: Of 1367 CRC patients, there were seven hundred and fifty-seven males (55.4%) and
610 (44.6%) females. The median follow-up period was 60 months (range, 3–132 months).
A multivariate analysis identified that low serum albumin level (P = 0.011), advanced UICC stage
(P < 0.001), and high carcinoembryonic antigen (CEA) level (P < 0.001) were independent
prognostic factors of cancer-specific survival. Meanwhile, a multivariate analysis showed age over
65 years (P < 0.001), advanced UICC stage (P < 0.001), and high CEA level (P < 0.001) were
independent prognostic factors of overall survival. Furthermore, combination of UICC stage,
serum CEA and albumin levels as predictors of cancer-specific survival showed that the poorer the
prognostic factors involved, the poorer the cancer-specific survival rate. Likewise, combination of
UICC stage, age and serum CEA level as predictors of overall survival showed that the poorer the
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Open Accessprognostic factors involved, the poorer the overall survival rate. Of these prognostic factors,
preoperative serum CEA level was the only significant prognostic factor for patients with stage II
and III CRCs in both cancer-specific and overall survival categories.
Conclusion: Preoperative serum albumin level, CEA level and age could prominently affect
postoperative outcome of CRC patients undergoing surgical treatment. In addition to conventional
UICC staging system, it might be imperative to take these additional characteristics of factors into
account in CRC patients prior to surgical treatment.
Background
Colorectal cancer (CRC) is the most common cancer and
also the third leading cause of cancer death in Taiwan,
and it is also a significant health problem. In Taiwan, it is
estimated that approximately 10000 CRC patients were
diagnosed, and over 4100 patients died of this disease in
2006 (http://www.doh.gov.tw/statistic/index.htm;
accessed in December 2008). The prognosis of CRC
patients is mainly dependent on several factors: patho-
logical, clinical and biological. Although pathologic
stage [International Union against Cancer (UICC)
classification] is useful for predicting prognosis in CRC
patients, it is difficult to accurately determine the stage
prior to surgical treatment [1]. Furthermore, it is well
known that patients with the same UICC stage colonic
and rectal cancers display survival heterogeneity, with
some patients exhibiting relatively short survival times.
Accordingly, the identification of more promising prog-
nostic factors that are indeed highly predictive of CRC
patients undergoing surgical treatment is mandatory. To
date, a number of studies have been extensively
conducted to explore the role of prognostic factors for
survival in patients with CRC. Of these parameters, age,
serum albumin, histology, and carcinoembryonic anti-
gen (CEA) levels have previously been demonstrated to
be powerful prognostic indicators for CRC patients [2-9].
However, information of an overall view of these factors
in combination is scant. Combining these important
prognostic factors might be important to be auxiliary to
the UICC staging system in preoperative accurate
prediction of cancer-specific and overall survival rates
for CRC patients more precisely. The aim of this study
was to identify clinical or pathologic variables that could
be used preoperatively to predict postoperative cancer-
specific and overall survival rates of CRC patients more
accurately, in addition to conventional UICC staging
systems.
Methods
Patients
This retrospective cohort study included 1422 consecu-
tive patients with histologically proven CRC who were
receiving surgical treatment at the Department of
Surgery, Kaohsiung Medical University Hospital. Patients
of postoperative mortality that was defined as death
within the first 30 days after operation (n = 23) and/or
having an incomplete record of medical charts (n = 32)
were excluded. A total remaining 1367 patients were
enrolled into this study. The study was approved by the
Institutional Hospital Board of the Kaohsiung Medical
University Hospital. Patients’ clinical outcomes and
survival status were regularly followed up till 31
December 2007. Available variables included: age of
onsets, sex, tumor location, preoperative serum albumin,
serum CEA, and TNM/UICC classification defined
according to the criteria of the American Joint Commis-
sion on Cancer/International Union against Cancer
(AJCC/UICC) [1]. We dichotomized continuous vari-
ables into two categories for statistical analysis including
age: those aged <65 years (n = 624) and those ≥65 years
(n = 743); serum albumin level: < 3.5 gm/dl (n = 392)
and those ≥3.5 gm/dl (n = 975); serum CEA level: <5 ng/
ml (n = 724) and ≥5 ng/ml (n = 643). All patients were
followed up until their death, and only patients who
died of CRC were included in the cancer-specific death
category. Cancer-specific survival was defined as the time
elapsed between primary surgery and death from CRC.
Overall survival was defined as the time elapsed between
primary surgery and death from any cause.
Statistical analysis
All data were statistically analyzed using the Statistical
Package for the Social Sciences, version 12.0 (SPSS Inc.,
Chicago, IL, USA). For the univariate statistical analysis,
Chi-square test was used where applicable. A Cox
proportional hazards model with forward stepwise
variable selection was used for multivariate testing of
those factors found to be significant by univariate
analysis (the inclusion factors were those with P value
less than 0.05 by univariate analysis). Overall and
cancer-specific survival rates were calculated by the
Kaplan-Meier method, and the differences in survival
rates were analyzed by the log-rank test. A P value less
than 0.05 was considered to be statistically significant.
Results
The clinical and pathologic data regarding 1367 CRC
p a t i e n t sa r es u m m a r i z e di nT a b l e1 .T h e r ew e r e7 5 7
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(page number not for citation purposes)(55.4%) males and 610 (44.6%) females. Nine hundred
and twenty (67.3%) patients had carcinoma of the
colon,and447(32.7%)hadcarcinomaoftherectum.The
median age of these patients was 66 years with a range of
19 to 95 years. Six hundred and twenty-four (45.6%)
cases were < 65 years old and seven hundred and forty-
three cases were (54.4%) ≥ 65 years old. With regard to
the histological type of these tumors, 183 (13.4%) were
well differentiated carcinoma, 1066 (77.9%) were mod-
erately differentiated carcinoma, and 118 (8.7%) were
poorly differentiated carcinoma. When classified with the
UICC staging system, there were 230 (16.8%) stage I
patients, 506 (37.1%) stage II patients, 391 (28.6%) stage
III patients, and 240 (17.5%) stage IV patients.
Using univariate analysis of cancer-specific survival, we
found that sex (P = 0.002), tumor size (P = 0.015), serum
albumin level (P < 0.001), histology (P <0 . 0 0 1 ) ,U I C C
stage (P <0 . 0 0 1 )a n ds e r u mC E Al e v e l( P < 0.001) were
statistically significant (Table 2). Moreover, Cox propor-
tional hazards regression analysis indicated that patients
with serum albumin levels < 3.5 gm/dl were 1.45 times
more likely to die of cancer than those whose serum
albumin levels ≥3.5 gm/dl (P = 0.011; HR, 1.25; 95% CI,
1.09–1.92); patients with UICC stage III/IV were 3.25
times more likely to die of cancer than those with UICC
stage I/II (P < 0.001; HR, 3.25; 95% CI, 2.42–4.36);
patients with serum CEA ≥5 ng/ml were 2.38 times more
likely to die of cancer than those whose serum CEA
<5 ng/ml (P < 0.001; HR, 2.38; 95% CI, 1.77–3.20) for
cancer-specific survival. Moreover, the combination of
UICC stage, serum CEA and serum albumin levels as
predictors of cancer-specific survival is shown in Table 3.
It was demonstrated, whatever the presence of any one
predictor, or any two predictors or all three predictors, to
be significant for cancer-specific survival of CRC patients
(all P < 0.001). Meanwhile, the increased risk of cancer-
specific survival is proportionate to the involved
numbers of these three variables. CRC patients with
serum CEA level < 5 ng/ml (P < 0.001; Figure 1) or
albumin level ≥ 3.5 gm/dl (P <0 . 0 0 1 ;F i g u r e2 )h a d
significantly greater cancer-specific survival rates than
those with serum CEA levels ≥ 5 ng/ml or albumin level
<3.5 gm/dl respectively. Moreover, CRC patients with
a g e<6 5y e a r s( P < 0.001; Figure 3) or serum CEA levels
<5n g / m l( P = 0.003; Figure 4) had significantly greater
overall survival rates than those with age = 65 years or
serum CEA levels ≥ 5 ng/ml respectively.
Table 4 shows the univariate and multivariate analysis of
overall survival, age (P =0 . 0 0 3 ) ,s e x( P = 0.026), tumor
size (P = 0.026), serum albumin level (P <0 . 0 0 1 ) ,
histology (P < 0.001), UICC stage (P < 0.001) and serum
Table 1: Demographic data in 1367 colorectal cancer patients
Variable Case No. Percentage (%)
Age
<65 years/≥65 years 624/743 45.6%/54.4%
Gender
Male/Female 757/610 55.4%/44.6%
Tumor size
≥5 cm/<5 cm 539/774 39.4%/60.6%
Tumor location
Colon/Rectum 920/447 67.3%/32.7%
Histological type
Well/Moderately/
Poorly
183/1066/118 13.4%/77.9%/8.7%
UICC
a Stage
I/II/III/IV 230/506/391/240 16.8%/37.1%/28.6%/17.5%
Tumor invasion
T1/T2/T3/T4 70/229/989/80 5.1%/16.7%/72.4%/5.8%
Node metastases
N0/N1/N2 832/343/192 60.8%/25.2%/14.0%
Serum Albumin level
<3.5 gm/dl/≥3.5 gm/dl 392/975 28.7%/71.3%
Serum CEA
blevel
≥5 ng/ml/<5 ng/ml 634/724 46.4%/53.6%
aInternational Union Against Cancer.
bCarcinoembrynic antigen.
Table 2: Univariate and multivariate analysis of prognostic indicators on cancer-specific survival for colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65)years 743/624 1.17(0.97–1.41) 0.930 - -
Sex (Male/Female) 757/610 1.24(1.03–1.50) 0.022 - 0.281
Site (Colon/Rectum) 920/447 1.19(0.98–1.46) 0.085 - -
Tumor size (≥5/<5)cm 539/774 1.28(1.05–1.56) 0.015 - 0.411
BMI
a (≥24/≥18.5–24/<18.5) 434/516/417 0.84(0.64–1.09) 0.185 - -
Albumin (<3.5/≥3.5)gm/dl 392/975 1.72(1.38–2.14) <0.001 1.45(1.09–1.92) 0.011
Histology (PD/MD/WD
b) 118/1066/183 3.05(1.95–4.77) <0.001 - 0.341
UICC
c stage (III&IV/I&II) 630/737 3.96(3.22–4.87) <0.001 3.25(2.42–4.36) <0.001
CEA
d (≥5/<5) ng/ml 643/724 2.91(2.34–3.62) <0.001 2.38(1.77–3.20) <0.001
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cInternational Union Against Cancer.
dCarcinoembrynic antigen.
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(page number not for citation purposes)Table 3: Combination of carcinoembryonic antigen, albumin supplementary to UICC
a staging system as predictors of colorectal
cancer for cancer specific survival by Cox regression analysis
Parameters Regression coefficient Standard error Hazard ratio (95% CI) P value
UICC
a stage (III&IV/I&II) 1.376 0.106 3.96(3.22–4.87) <0.001
UICC
a Stage III&IV and serum CEA
b ≥5 ng/ml 2.162 0.172 8.69(6.20–12.18) <0.001
UICC
a Stage III&IV and serum CEA
b ≥5 ng/ml and serum albumin
<3 . 5g m / d l
2.794 0.264 16.347(9.735–27.450) <0.001
aInternational Union Against Cancer.
bCarcinoembrynic antigen.
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Figure 1
Cumulative cancer-specific survival rates of patients
with colorectal cancer according to serum albumin
level (P <0 . 0 0 1 ) .
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Figure 2
Cumulative cancer-specific survival rates of patients
with colorectal cancer according to serum
carcinoembryonic antigen (CEA) level (P <0 . 0 0 1 ) .
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Figure 3
Cumulative overall survival rates of patients with
colorectal cancer according to age (P =0 . 0 0 3 ) .
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Figure 4
Cumulative overall survival rates of patients with
colorectal cancer according to serum
carcinoembryonic antigen (CEA) level (P <0 . 0 0 1 ) .
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(page number not for citation purposes)CEA level (P < 0.001) were significantly correlated to
overall survival by univariate analysis. Furthermore, Cox
proportional hazards regression analysis indicated that
patients over 65 years of age were 1.85 times more likely
to die of cancer than those under 65 years of age
(P < 0.001; HR, 1.85; 95% CI, 1.41–2.43); patients with
UICC stage III/IV were 3.09 times more likely to die of
cancer than those with UICC stage I/II (P < 0.001; HR,
3.09; 95% CI, 2.34–4.07); patients with serum CEA ≥ 5
ng/ml were 2.28 times more likely to die of cancer than
those whose serum CEA <5 ng/ml (P < 0.001; HR, 2.28;
95% CI, 1.73–3.01) for overall survival. Moreover, the
combination of age, UICC stage, and serum CEA level as
predictors of overall survival is shown in Table 5. It was
demonstrated, whatever the presence of any one
predictor, or any two predictors or all three predictors,
to be significant for cancer-specific survival of CRC
patients (all P < 0.001). Similarly, the increased risk of
overall survival was proportionate to the involved
numbers of these three variables.
To identify the promising prognostic factors of cancer-
specific and overall survival rates in stage II or stage III
CRC patients preoperatively, we further tried to analyze
stage II and III CRC patients respectively. Of these
factors, preoperative serum CEA level was the only
significant prognostic factor for patients with stage II
( T a b l e s6a n d7 )a n dI I I( T a b l e s8a n d9 )C R C si nb o t h
cancer-specific and overall survival categories (all
P < 0.005), despite age was also one independent
prognostic factor of overall survival in stage II and III
CRC patients.
Discussion
This current study revealed the association of preopera-
tive serum albumin level, CEA level and age with survival
of CRC patients undergoing surgical treatment, which is
adjuvant to conventional UICC staging system. Particu-
larly, our study demonstrated that combining preopera-
tive serum albumin level, CEA level and UICC stage
significantly affect the cancer-specific survival of patients
with CRC postoperatively. Meanwhile, the combination
of serum CEA level, age and UICC stage prominently
affected the overall survival of CRC patients postopera-
tively. In contrast to UICC pathological stage, the
upmost important meaning is that these three factors
including serum albumin level, CEA level, and age could
be available preoperatively.
Consistent with previous investigations [5,8,10,11],
preoperative low serum albumin may be a vital indicator
and may predict an unfavorable prognosis for CRC
patients. Serum albumin level has been traditionally
used as a biochemical marker of individual nutritional
status. Hypoalbuminemia is associated with the presence
Table 4: Univariate and multivariate analysis of prognostic indicators on overall survival for colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65) years 743/624 1.30(1.09–1.56) 0.004 1.85(1.41–2.43) <0.001
Sex (Male/Female) 757/610 1.22(1.03–1.46) 0.026 - 0.186
Site (Colon/Rectum) 920/447 1.20(0.99–1.45) 0.066 - -
Tumor size (≥5/<5) cm 593//774 1.24(1.03–1.50) 0.026 - 0.256
BMI
a (≥24/<18.5–24/<18.5) 434/516/417 0.84(0.66–1.09) 0.186 - -
Albumin (<3.5/≥3.5) gm/dl 392/975 1.70(1.38–2.10) <0.001 - 0.072
Histology (PD/MD/WD
b) 118/1066/183 2.92(1.91–4.49) <0.001 - 0.245
UICC
c stage (III&IV/I&II) 630/737 3.45(2.84–4.18) <0.001 3.09(2.34–4.07) <0.001
CEA
d(≥5/<5) ng/ml 643/724 2.74(2.23–3.37) <0.001 2.28(1.73–3.01) <0.001
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cInternational Union Against Cancer.
dCarcinoembrynic antigen.
Table 5: Combination of carcinoembryonic antigen, age supplementary to UICC
a staging system as predictors of colorectal cancer for
cancer overall survival by Cox regression analysis
Parameters Regression coefficient Standard error Hazard ratio (95% CI) P value
UICC
a stage (III&IV/I&II) 1.238 0.099 3.45(2.84–4.18) <0.001
UICC
a Stage III&IV and serum CEA
b ≥5 ng/ml 1.979 0.157 7.23(5.31–9.85) <0.001
UICC
a Stage III&IV and serum CEA
b ≥5 ng/ml and age ≥65 years 2.222 0.203 9.22(6.19–13.74) <0.001
aInternational Union Against Cancer.
bCarcinoembrynic antigen.
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(page number not for citation purposes)of a systemic inflammatory response, weight loss and
metastatic tumor volume [12,13]. Moreover, serum
a l b u m i nm e a s u r e m e n ti sp a r to ft h el i v e rf u n c t i o nt e s t
battery, and for most patients it is measured even before
cancer is diagnosed and before the staging protocol or
the treatment program. The potential advantage of
serum albumin level as a preoperative prognostic factor
in CRC patients is that it is inexpensive, reproducible
and powerful. Our results demonstrated that low serum
albumin was an independent significant prognostic
factor, even after adjusting for potential confounding
factors. The possible explanation for the association
between low serum albumin and poor survival in CRC
patients might be due to cancer cachexia [5]. Besides, low
serum albumin level is indicative of an ongoing systemic
response, which causes the loss of body weight and body
protein [5,10].
Since the first description in 1965, CEA has remained the
most regularly examined tumor marker [14]. CEA is a
Table 8: Univariate and multivariate analysis of prognostic indicators on cancer-specific survival for stage III colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65)years 189/193 1.33(0.90–1.96) 0.148 - -
Sex (Male/Female) 198/184 0.74(0.52–1.05) 0.092 - -
Site (Colon/Rectum) 263/119 0.96(0.66–1.40) 0.818 - -
Tumor size (≥5/<5)cm 170/212 1.24(0.86–1.78) 0.252 - -
BMI
a (≥24/≥18.5–24/<18.5) 123/150/109 1.01(0.63–1.61) 0.984 - -
Albumin (<3.5/≥3.5)gm/dl 110/272 1.35(0.85–2.15) 0.207 - -
Histology (PD/MD/WD
b) 62/278/42 2.11(0.91–4.92) 0.083 - -
CEA
c (≥5/<5) ng/ml 193/189 1.74(1.22–2.50) 0.002 1.74(1.22–2.50) 0.002
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cCarcinoembrynic antigen.
Table 7: Univariate and multivariate analysis of prognostic indicators on overall survival for stage II colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65) years 290/205 1.97(1.33–2.91) 0.001 1.72(1.05–2.82) 0.003
Sex (Male/Female) 281/214 1.80(0.76–1.54) 0.670 - -
Site (Colon/Rectum) 334/161 1.03(0.71–1.51) 0.864 - -
Tumor size (≥5/<5) cm 253/242 1.04(0.72–1.49) 0.843 - -
BMI
a (≥24/<18.5–24/<18.5) 146/185/164 0.94(0.54–1.63) 0.969 - -
Albumin (<3.5/≥3.5) gm/dl 169/326 1.79(1.17–2.75) 0.008 - 0.138
Histology (PD/MD/WD
b) 48/367/80 2.42(0.97–6.03) 0.057 - -
CEA
c(≥5/<5) ng/ml 214/281 2.08(1.39–3.13) <0.001 2.17(1.39–3.40) 0.001
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cCarcinoembrynic antigen.
Table 6: Univariate and multivariate analysis of prognostic indicators on cancer-specific survival for stage II colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65)years 290/205 1.68(1.11–2.53) 0.014 - 0.190
Sex (Male/Female) 281/214 1.15(0.78–1.69) 0.492 - -
Site (Colon/Rectum) 334/161 1.02(0.68–1.53) 0.940 - -
Tumor size (≥5/<5)cm 253/242 1.12(0.76–1.66) 0.572 - -
BMI
a (≥24/≥18.5–24/<18.5) 146/185/164 0.82(0.45–1.51) 0.527 - -
Albumin (<3.5/≥3.5)gm/dl 169/326 1.86(1.17–2.97) 0.009 - 0.101
Histology (PD/MD/WD
b) 48/367/80 2.59(0.96–6.95) 0.060 - -
CEA
c (≥5/<5) ng/ml 214/281 2.14(1.37–3.34) 0.001 2.39(1.46–3.90) <0.001
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cCarcinoembrynic antigen.
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(page number not for citation purposes)high-molecular weight glycoprotein in the immunoglo-
bulin superfamily of molecules, that plays a pivotal role
in such biological phenomena as adhesion, immunity or
apoptosis of the tumor cells and assessment of sensitivity
to anti-tumor agents [15,16]. High serum CEA has been
shown to be associated with a number of malignancies,
including those of colorectal, breast, pancreas and lung
types. Previous studies have shown that preoperative
high serum CEA is associated with a poor prognosis
[2-7,17-21]. Our results demonstrated that high serum
CEA was an independent significant prognostic factor of
all CRC patients and stage II/III CRC patients, even after
adjusting for potential confounding factors. We found
that high serum CEA levels were associated with poor
survival in CRC patients, and the possible reason might
result from increased tumor volume leading to a higher
incidence of postoperative metastasis. Dixon et al. have
demonstrated that patients with high CEA and low
albumin levels likely reflect some type of systemic
compromise from an activation of a metabolically active
tumor, exhibiting a significantly decreased survival time
in CRC patients [5]. However, these presumptions await
further investigation for confirmation. We are endeavor-
ing to find more efficient ways of combining indepen-
dent factors instead of using single independent factors
alone to predict survival time. Our results also reveal that
combining serum albumin level, serum CEA level and
UICC stage could be more accurate to predict cancer-
specific survival rates of CRC patients.
On the other hand, several studies have also shown that
old age is an independent prognostic factor associated
with poor prognosis in CRC patients [22-25]. The higher
postoperative morbidity rate in the older age patient
group is because of the significant enhancement in
common postoperative complications. Consistent with
our observation, Schiffmann et al. also revealed that the
worse prognosis was in older CRC patients [24]. Older
age may be associated with cardiovascular diseases or
other medical illness [26], and with the significantly
higher American Society of Anesthesiologists (ASA) classi-
fications [27]; hence, older age is associated with poor
overall survival, but not cancer-specific survival, in CRC
patients. Actually, patient age has a decisive impact on the
short-term postoperative outcome of patients undergoing
surgery for CRC [28]. Ultimately, our current study suggests
that cancer-specific and overall mortality should be
considered separately in survival analysis of CRC patients.
Conclusion
In conclusion, preoperative serum albumin level, CEA
level and age could affect postoperative outcome of CRC
patients undergoing surgical treatment. Of these factors,
preoperative serum CEA level is the only significant
prognostic factor for patients with stage II and III CRCs.
Preoperatively, the identified prognostic factors supple-
mentary to UICC staging system may be potentially
useful to improve the prediction of cancer-specific
survival and overall survival in CRC patients. However,
it will be necessary to analyze clinical data from multiple
institutions to find additional related variables in order
to develop a more efficient and accurate way for
predicting surgical outcome of CRC patients.
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Table 9: Univariate and multivariate analysis of prognostic indicators on overall survival for stage III colorectal cancer patients
Parameters Number Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≥65/<65) years 189/193 1.87(1.33–2.65) <0.001 1.87(1.33–2.65) <0.001
Sex (Male/Female) 198/184 1.38(0.96–2.00) 0.086 - -
Site (Colon/Rectum) 263/119 1.01(0.70–1.46) 0.961 - -
Tumor size (≥5/<5) cm 170/212 1.17(0.82–1.65) 0.393 - -
BMI
a (≥24/<18.5–24/<18.5) 123/150/109 0.99(0.63–1.59) 0.987 - -
Albumin (<3.5/≥3.5) gm/dl 110/272 1.38(0.89–2.14) 0.156 - -
Histology (PD/MD/WD
b) 62/278/42 2.15(0.97–4.74) 0.058 - -
CEA
c(≥5/<5) ng/ml 193/189 1.43(1.02–2.02) 0.039 1.43(1.02–2.02) 0.039
aBody mass index.
bPoorly differentiated; Moderately differentiated; Well differentiated.
cCarcinoembrynic antigen.
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